Wednesday Jul 16 | BioSpace
Dicerna Pharmaceuticals, a Second Generation RNA Interference...
Dicerna Pharmaceuticals, Inc. , an RNA interference company developing novel therapeutics utilizing proprietary Dicer Substrate Technology , today announced a second closing of its Series A financing, receiving ...
Wednesday Jul 16 | The Boston Globe
Mass. gets $9.2m as drug maker settles with states
Massachusetts Attorney General Martha Coakley's office said it will receive just over $9.2 million from Bristol-Myers Squibb Co.
Alnylam Provides Update on "Glover" Patent
CAMBRIDGE, Mass. - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that the Glover patent , which is exclusively licensed to Alnylam from Cancer Research Technology Limited ...
Silence Therapeutics Announces Successful Opposition of Glover Patent
LONDON, July 11 Silence-Therapeutics LONDON , /PRNewswire/ -- Silence Therapeutics plc , a leading European RNA interference focused biotechnology company, announced today the successful opposition of a ...
Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies
CAMBRIDGE, Mass. & CARLSBAD, Calif.-- --Jun 24, 2008 - Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc.
Alnylam Signs Japanese Partner for RNAi-Based RSV Program
Alnylam Pharmaceuticals Inc. inked its third significant deal of the year, signing an exclusive alliance agreement to develop and commercialize ALN-RSV01, its lead RNAi therapeutic for the treatment of ...
Alnylam Pharmaceuticals Ties Up with Kyowa Hakko Kogyo Co., Ltd. on...
Alnylam Pharmaceuticals Ties Up with Kyowa Hakko Kogyo Co., Ltd. on Respiratory Drug in Asia; Alnylam to Receive $15M Upfront Payment and $78M Milestone Payments 6/19/2008 CAMBRIDGE, Mass.
RNAi specialist, Japanese drugmaker team up for Asian market in a deal worth up to $1 billion Rick Mullin U.S.-based Alnylam Pharmaceuticals and Japan's Takeda Pharmaceutical have formed an alliance to develop ...
Alnylam Announces Close of Investment and Expanded Agreement Related...
CAMBRIDGE, Mass. - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced the closing of its investment in and completion of its expanded agreement with Tekmira Pharmaceuticals ...
Mergers for Alnylam Create Risk
Mergers for Alnylam Create Risk Posted Fri May 30, 04:47 pm ET Posted By: Grant Zeng, CFA Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi ...
Isis to Receive $4.6 Million From Alnylam
Isis Pharmaceuticals, Inc. announced today that it will receive $4.6 million dollars from Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals and Takeda Pharmaceutical Co. Ltd. have formed a strategic platform alliance in RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional ...
Small-molecule startups attract execs, investors
“I think there's certainly a resurgence in the interest in (chemical drugs)”
Mass High Tech: The Journal of New England Technology - by Ryan Mcbride Mass High Tech Sandie Allen Avila Therapeutics’ band of doctorate brothers include, from left, Russell Petter, co-founder and CSO ... via Mass High Tech
Alnylam Pharmaceuticals narrows 1st-quarter loss
THE REGION Alnylam Pharmaceuticals Inc.'s share rose 9 percent after the Cambridge biotechnology company posted a smaller-than-expected first-quarter loss and strong revenue growth. via Boston Globe
Alnylam to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
May 12, 2008 - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that management will present a company overview at the Rodman & Renshaw 5th Annual Global Healthcare ... via Med Ad News
Novartis buys more Alnylam stock
Swiss pharmaceutical giant Novartis AG has upped its ownership stake in Alnylam Pharmaceuticals Inc. via Boston Business Journal
VIDEO: Biotech Stocks to Watch: Amylin Pharmaceuticals, Gilead...
Amylin Pharmaceuticals Ammending Pact with Eli Lilly Concerning U.S. Marketing; Gilead Sciences CEO John Martin Takes on Additional Duties as Board Chairman; Novartis to Buy Another 214K Addtional Unregistered ... via ClipSyndicate
Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 213,888 unregistered shares of Alnylam's common ... via BioSpace
Public relations, press release distribution, investor relations, SEC filing
Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that it will report financial results for the first - 05/02/2008 - 04:00 PM MINNEAPOLIS-- --Urologix , Inc. via Business Wire
Alnylam And Collaborators Publish Research On The Immunostimulatory...
“This new study continues to expand Alnylam's scientific leadership in the field of RNAi research as it represents continued understanding and refinement of our discovery process where - drug-like' properties of siRNAs can be readily achieved”
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced the publication of a study in the Journal of Interferon & Cytokine Research by scientists at Alnylam Europe , and collaborators, ... via BioResearch Online